{"DataElement":{"publicId":"3126077","version":"1","preferredName":"Post Treatment Study Follow-up Agent Name","preferredDefinition":"Text name for an agent taken by an individual during the post-therapy or followup portion of the patient's treatment plan.","longName":"POST_TX_FU_AGT_NM","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"3126073","version":"1","preferredName":"Post Treatment Study Follow-up Agent Name","preferredDefinition":"Post; occuring after._A type of study protocol designed to evaluate intervention(s) for disease treatment._The process by which information about the health status of an individual is obtained after a study has officially closed._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)_The words or language units by which a thing is known.","longName":"POST_TX_FU_AGT_NM","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"3126071","version":"1","preferredName":"Post Treatment Study Follow-up Agent","preferredDefinition":"Post; occuring after.:A type of study protocol designed to evaluate intervention(s) for disease treatment.:The process by which information about the health status of an individual is obtained after a study has officially closed.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C38008:C49656:C16033:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Treatment Study","conceptCode":"C49656","definition":"A type of study protocol designed to evaluate intervention(s) for disease treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Follow-Up","conceptCode":"C16033","definition":"The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8CEC0A18-E58C-C2CC-E040-BB89AD435688","latestVersionIndicator":"Yes","beginDate":"2010-08-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2222841","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6211245-8062-4DD9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER_EVS","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8CEC0A18-E59A-C2CC-E040-BB89AD435688","latestVersionIndicator":"Yes","beginDate":"2010-08-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3126076","version":"1","preferredName":"Post-Therapy Agent Name","preferredDefinition":"Occurring after a therapeutic procedure._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)_The words or language units by which a thing is known.","longName":"POSTTX_AGT_NM","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"80","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Nilotinib","valueDescription":"Nilotinib","ValueMeaning":{"publicId":"2737467","version":"1","preferredName":"Nilotinib","longName":"2737467","preferredDefinition":"An orally available aminopyrimidine with antineoplastic activity. Designed to overcome imatinib resistance, Nilotinib is a tyrosine kinase inhibitor that binds to and inhibits the Bcr-Abl fusion protein, an abnormal chimeric tyrosine kinase expressed in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and for c-kit, a receptor tyrosine kinase activated in gastrointestinal stromal tumor (GIST). Nilotinib interrupts phosphorylation of these tyrosine kinases and their downstream signaling targets, resulting in decreased cellular proliferation and the induction of apoptosis. This agent is more potent than imatinib against Ph+ CML cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilotinib","conceptCode":"C48375","definition":"An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C391-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8D27F6F2-0643-E00B-E040-BB89AD431B4C","beginDate":"2010-08-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-06","modifiedBy":"ONEDATA","dateModified":"2010-08-06","deletedIndicator":"No"},{"value":"Abiraterone","valueDescription":"Abiraterone","ValueMeaning":{"publicId":"3124284","version":"1","preferredName":"Abiraterone","longName":"3124284v1.00","preferredDefinition":"A steroidal compound with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abiraterone","conceptCode":"C77333","definition":"A steroidal compound with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C0EAA9F-D692-4F99-E040-BB89AD435CFD","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F3AD-77C5-E040-BB89AD437145","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Advair","valueDescription":"Advair (Fluticasone-salmeterol)","ValueMeaning":{"publicId":"3076455","version":"1","preferredName":"Advair (Fluticasone-salmeterol)","longName":"3076455","preferredDefinition":"Advair (Fluticasone-salmeterol)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"852693AD-C730-32F2-E040-BB89AD436CB9","latestVersionIndicator":"Yes","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F3B7-77C5-E040-BB89AD437145","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Albuterol","valueDescription":"Albuterol (Proventil, Ventolin, Volmax)","ValueMeaning":{"publicId":"2575988","version":"1","preferredName":"Albuterol (Proventil, Ventolin, Volmax)","longName":"2575988","preferredDefinition":"A racemic mixture with a 1:1 ratio of the r-isomer, levalbuterol, and s-albuterol. It is a short-acting beta2-adrenergic agonist with its main clinical use in asthma. (MeSH)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Albuterol","conceptCode":"C215","definition":"A racemic mixture of the r-isomer levalbuterol and s-albuterol, a short-acting sympathomimetic agent with bronchodilator activity. Albuterol stimulates beta-2 adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP concentrations relax bronchial smooth muscle, relieve bronchospasms, and reduce inflammatory cell mediator release, especially from mast cells. Albuterol although to a lesser extent, also stimulates beta-1 adrenergic receptors, thereby increasing the force and rate of myocardial contraction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5E1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2010-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F3C1-77C5-E040-BB89AD437145","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Anti-IGF-1R Recombinant Monoclonal Antibody SCH 717454","valueDescription":"Anti-IGF-1R Recombinant Monoclonal Antibody SCH 717454","ValueMeaning":{"publicId":"2958646","version":"1","preferredName":"Anti-IGF-1R Recombinant Monoclonal Antibody SCH 717454","longName":"2958646","preferredDefinition":"A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Anti-IGF-1R fully human monoclonal antibody SCH 717454 binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; downregulation of this survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Robatumumab","conceptCode":"C71527","definition":"A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Anti-IGF-1R fully human monoclonal antibody SCH 717454 binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; downregulation of this survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77A5BE05-4414-2754-E040-BB89AD435329","latestVersionIndicator":"Yes","beginDate":"2009-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F3CB-77C5-E040-BB89AD437145","beginDate":"2009-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Azithromycin","valueDescription":"Azithromycin (Zithromax)","ValueMeaning":{"publicId":"3076456","version":"1","preferredName":"Azithromycin (Zithromax)","longName":"3076456","preferredDefinition":"An azalide, derived from erythromycin, and a member of a subclass of macrolide antibiotics with bacteriocidal and bacteriostatic activities. Azithromycin reversibly binds to the 50S ribosomal subunit of the 70S ribosome of sensitive microorganisms, thereby inhibiting the translocation step of protein synthesis, wherein a newly synthesized peptidyl tRNA molecule moves from the acceptor site on the ribosome to the peptidyl (donor) site, and consequently inhibiting RNA-dependent protein synthesis leading to cell growth inhibition and cell death. [Source: NCI]","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azithromycin","conceptCode":"C28844","definition":"An azalide, derived from erythromycin, and a member of a subclass of macrolide antibiotics with bacteriocidal and bacteriostatic activities. Azithromycin reversibly binds to the 50S ribosomal subunit of the 70S ribosome of sensitive microorganisms, thereby inhibiting the translocation step of protein synthesis, wherein a newly synthesized peptidyl tRNA molecule moves from the acceptor site on the ribosome to the peptidyl (donor) site, and consequently inhibiting RNA-dependent protein synthesis leading to cell growth inhibition and cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"852693AD-C753-32F2-E040-BB89AD436CB9","latestVersionIndicator":"Yes","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F3D5-77C5-E040-BB89AD437145","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Cabazitaxel","valueDescription":"Cabizitaxel","ValueMeaning":{"publicId":"2939033","version":"1","preferredName":"Cabizitaxel","longName":"2939033v1.00","preferredDefinition":"A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cabazitaxel","conceptCode":"C66937","definition":"A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72F42843-4B01-DE11-E040-BB89AD43432F","latestVersionIndicator":"Yes","beginDate":"2009-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F3DF-77C5-E040-BB89AD437145","beginDate":"2009-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Ch 14.18 Monoclonal Antibody","valueDescription":"Ch 14.18 Monoclonal Antibody (Anti-GD-2 Monoclonal Antibody)","ValueMeaning":{"publicId":"3021176","version":"1","preferredName":"Ch 14.18 Monoclonal Antibody (Anti-GD-2 Monoclonal Antibody)","longName":"3021176","preferredDefinition":"Ch 14.18 Monoclonal Antibody (Anti-GD-2 Monoclonal Antibody)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"817312F9-59B3-37DB-E040-BB89AD437AE8","latestVersionIndicator":"Yes","beginDate":"2010-03-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F3E9-77C5-E040-BB89AD437145","beginDate":"2010-03-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Cytarabine","valueDescription":"Cytarabine (Ara C, Cytosine Arabinoside)","ValueMeaning":{"publicId":"2960387","version":"1","preferredName":"Cytarabine (Ara C, Cytosine Arabinoside)","longName":"2960387","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"780B7F9B-CE25-2E47-E040-BB89AD431007","latestVersionIndicator":"Yes","beginDate":"2009-11-10","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F3F3-77C5-E040-BB89AD437145","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Epithilone B","valueDescription":"Epothilone B","ValueMeaning":{"publicId":"3013195","version":"1","preferredName":"Epothilone B","longName":"3013195","preferredDefinition":"A compound isolated from the myxobacterium Sorangium cellulosum.  Similar to paclitaxel, epothilone B induces microtubule polymerization and stabilizes microtubules against depolymerization conditions.  In addition to promoting tubulin polymerization and stabilization of microtubules, this agent is cytotoxic for cells overexpressing P-glycoprotein, a characteristic that distinguishes it from the taxanes.  Epothilone B may cause complete cell-cycle arrest. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patupilone","conceptCode":"C1623","definition":"A compound isolated from the myxobacterium Sorangium cellulosum.  Similar to paclitaxel, patupilone induces microtubule polymerization and stabilizes microtubules against depolymerization conditions.  In addition to promoting tubulin polymerization and stabilization of microtubules, this agent is cytotoxic for cells overexpressing P-glycoprotein, a characteristic that distinguishes it from the taxanes.  Patupilone may cause complete cell-cycle arrest.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FF9397D-42B1-21AE-E040-BB89AD436688","latestVersionIndicator":"Yes","beginDate":"2010-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F3FD-77C5-E040-BB89AD437145","beginDate":"2010-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Extracorporeal Photopheresis","valueDescription":"Extracorporeal Photopheresis","ValueMeaning":{"publicId":"2777671","version":"1","preferredName":"Extracorporeal Photopheresis","longName":"2777671","preferredDefinition":"A procedure in which blood is removed from the body and treated with ultraviolet light and drugs that become active when exposed to light. The blood is then returned to the body. It is being studied in the treatment of some blood and bone marrow diseases and graft-vs-host disease (GVHD).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extracorporeal Photopheresis","conceptCode":"C62729","definition":"A procedure which combines apheresis and photodynamic therapy, resulting in blood being treated with a photosensitizing agent and subsequently irradiated with specified wavelengths of light to achieve an effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"554B1B7C-0FF8-6EED-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F407-77C5-E040-BB89AD437145","beginDate":"2010-07-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Fluticasone","valueDescription":"Fluticasone Propionate (Flovent)","ValueMeaning":{"publicId":"3076454","version":"1","preferredName":"Fluticasone Propionate (Flovent)","longName":"3076454","preferredDefinition":"The propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2, which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.: A synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Fluticasone binds and activates glucocorticoid receptor, resulting in the activation of lipocortin. Lipocortin, in turn, inhibits cytosolic phospholipase A2, which triggers a cascade of reactions involved in the synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluticasone Propionate","conceptCode":"C29061","definition":"The propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2, which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Fluticasone","conceptCode":"C61767","definition":"A synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Fluticasone binds and activates glucocorticoid receptor, resulting in the activation of lipocortin. Lipocortin, in turn, inhibits cytosolic phospholipase A2, which triggers a cascade of reactions involved in the synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"852693AD-C70D-32F2-E040-BB89AD436CB9","latestVersionIndicator":"Yes","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F411-77C5-E040-BB89AD437145","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Foretinib","valueDescription":"Multitargeted Tyrosine Kinase Inhibitor GSK1363089","ValueMeaning":{"publicId":"3124282","version":"1","preferredName":"Multitargeted Tyrosine Kinase Inhibitor GSK1363089","longName":"3124282","preferredDefinition":"An orally bioavailable small molecule with potential antineoplastic activity. MET/VEGFR2 inhibitor GSK1363089 binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto-oncogene c-MET has been found to be over-expressed in a variety of cancers. VEGFR2 is found on endothelial and hematopoietic cells and mediates the development of the vasculature and hematopoietic cells through VEGF signaling.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Foretinib","conceptCode":"C80058","definition":"An orally bioavailable small molecule with potential antineoplastic activity. Foretinib binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto-oncogene c-MET has been found to be over-expressed in a variety of cancers. VEGFR2 is found on endothelial and hematopoietic cells and mediates the development of the vasculature and hematopoietic cells through VEGF signaling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C0EAA9F-D66C-4F99-E040-BB89AD435CFD","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F41B-77C5-E040-BB89AD437145","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Fostamatinib Disodium","valueDescription":"Fostamatinib Disodium","ValueMeaning":{"publicId":"2939032","version":"1","preferredName":"Fostamatinib Disodium","longName":"2939032","preferredDefinition":"An orally available disodium salt of the Syk kinase inhibitor fostamatinib with potential anti-inflammatory and immunomodulating activities. Fostamatinib inhibits Syk kinase-mediated IgG Fc gamma receptor signaling, resulting in inhibition of the activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage. Syk kinase, widely expressed in hematopoietic cells, is a nonreceptor tyrosine kinase that is involved in coupling activated immunoreceptors to signal downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fostamatinib Disodium","conceptCode":"C69128","definition":"An orally available disodium salt of the Syk kinase inhibitor fostamatinib with potential anti-inflammatory and immunomodulating activities. Fostamatinib inhibits Syk kinase-mediated IgG Fc gamma receptor signaling, resulting in inhibition of the activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage. Syk kinase, widely expressed in hematopoietic cells, is a nonreceptor tyrosine kinase that is involved in coupling activated immunoreceptors to signal downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72F42843-4ADE-DE11-E040-BB89AD43432F","latestVersionIndicator":"Yes","beginDate":"2009-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F425-77C5-E040-BB89AD437145","beginDate":"2009-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Hsp90 Inhibitor STA-9090","valueDescription":"Hsp90 Inhibitor STA-9090","ValueMeaning":{"publicId":"3061618","version":"1","preferredName":"Hsp90 Inhibitor STA-9090","longName":"3061618","preferredDefinition":"A synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor STA-9090 binds to and inhibits Hsp90, resulting in the proteasomal degradation of oncogenic client proteins, the inhibition of cell proliferation and the elevation of heat shock protein 72 (Hsp72); it may inhibit the activity of multiple kinases, such as c-Kit, EGFR, and Bcr-Abl, which as client proteins depend on functional HsP90 for maintenance. Hsp90, a 90 kDa molecular chaperone upregulated in a variety of tumor cells, plays a key role in the conformational maturation, stability and function of \"client\" proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors.  Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ganetespib","conceptCode":"C77872","definition":"A synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Ganetespib binds to and inhibits Hsp90, resulting in the proteasomal degradation of oncogenic client proteins, the inhibition of cell proliferation and the elevation of heat shock protein 72 (Hsp72); it may inhibit the activity of multiple kinases, such as c-Kit, EGFR, and Bcr-Abl, which as client proteins depend on functional HsP90 for maintenance. Hsp90, a 90 kDa molecular chaperone upregulated in a variety of tumor cells, plays a key role in the conformational maturation, stability and function of \"client\" proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors.  Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8496A11C-C12A-2BBD-E040-BB89AD4333D9","latestVersionIndicator":"Yes","beginDate":"2010-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F42F-77C5-E040-BB89AD437145","beginDate":"2010-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Iodine-131","valueDescription":"Iodine I 131","ValueMeaning":{"publicId":"2939366","version":"1","preferredName":"Iodine I 131","longName":"2939366","preferredDefinition":"A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iodine I-131","conceptCode":"C1639","definition":"A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7339449B-399C-92A9-E040-BB89AD435E25","latestVersionIndicator":"Yes","beginDate":"2009-09-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F439-77C5-E040-BB89AD437145","beginDate":"2009-09-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Ipratropium","valueDescription":"Ipratropium","ValueMeaning":{"publicId":"3076449","version":"1","preferredName":"Ipratropium","longName":"3076449","preferredDefinition":"A synthetic derivative of the alkaloid atropine with anticholinergic properties. Ipratropium antagonizes the actions of acetylcholine at parasympathetic postganglionic effector cell junctions. When inhaled, ipratropium binds competitively to cholinergic receptors in the bronchial smooth muscle thereby blocking the bronchoconstrictor actions of the acetylcholine (Ach) mediated vagal impulses. Inhibition of the vagal tone leads to dilation of the large central airways resulting in bronchodilation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipratropium","conceptCode":"C61794","definition":"A synthetic derivative of the alkaloid atropine with anticholinergic properties. Ipratropium antagonizes the actions of acetylcholine at parasympathetic postganglionic effector cell junctions. When inhaled, ipratropium binds competitively to cholinergic receptors in the bronchial smooth muscle thereby blocking the bronchoconstrictor actions of the acetylcholine (Ach) mediated vagal impulses. Inhibition of the vagal tone leads to dilation of the large central airways resulting in bronchodilation.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"852693AD-C690-32F2-E040-BB89AD436CB9","latestVersionIndicator":"Yes","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F443-77C5-E040-BB89AD437145","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Levalbuterol","valueDescription":"Levalbuterol (Xopenex)","ValueMeaning":{"publicId":"3076450","version":"1","preferredName":"Levalbuterol (Xopenex)","longName":"3076450v1.00","preferredDefinition":"A short-acting sympathomimetic beta-2 adrenergic receptor agonist with bronchodilator activity. Levalbuterol binds to beta-2 adrenergic receptors in bronchial smooth muscle and activates intracellular adenyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP levels lead to the activation of protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation of bronchial smooth muscles. The increased cAMP concentrations also inhibit the release of inflammatory mediators, especially from mast cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levalbuterol","conceptCode":"C74196","definition":"A short-acting sympathomimetic beta-2 adrenergic receptor agonist with bronchodilator activity. Levalbuterol binds to beta-2 adrenergic receptors in bronchial smooth muscle and activates intracellular adenyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP levels lead to the activation of protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation of bronchial smooth muscles. The increased cAMP concentrations also inhibit the release of inflammatory mediators, especially from mast cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"852693AD-C6B5-32F2-E040-BB89AD436CB9","latestVersionIndicator":"Yes","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F44D-77C5-E040-BB89AD437145","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Lexatumumba","valueDescription":"Lexatumumba","ValueMeaning":{"publicId":"2967120","version":"1","preferredName":"Lexatumumba","longName":"2967120","preferredDefinition":"Lexatumumba","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7AB133FF-9818-BF80-E040-BB89AD43245B","latestVersionIndicator":"Yes","beginDate":"2009-12-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F457-77C5-E040-BB89AD437145","beginDate":"2009-12-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine","valueDescription":"Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine","ValueMeaning":{"publicId":"2958647","version":"1","preferredName":"Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine","longName":"2958647","preferredDefinition":"Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77A5BE05-4437-2754-E040-BB89AD435329","latestVersionIndicator":"Yes","beginDate":"2009-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F461-77C5-E040-BB89AD437145","beginDate":"2009-11-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"MEGF0444A","valueDescription":"MEGF0444A (Humanized IgG1 Antibody)","ValueMeaning":{"publicId":"3076402","version":"1","preferredName":"MEGF0444A (Humanized IgG1 Antibody)","longName":"3076402v1.00","preferredDefinition":"A humanized IgG1 monoclonal antibody directed against the epidermal growth factor-like domain multiple 7 (EGFL7) with potential antineoplastic activity. Parsatuzumab binds to EGFL7, thereby preventing the activities of EGFL7 on endothelial cells and inhibiting the survival and migration of endothelial cells during angiogenesis. EGFL7, a vascular-restricted extracellular matrix protein which is upregulated during angiogenesis and which regulates vascular development, may be overexpressed on the cell surfaces of various solid tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Parsatuzumab","conceptCode":"C90567","definition":"A humanized IgG1 monoclonal antibody directed against the epidermal growth factor-like domain multiple 7 (EGFL7) with potential antineoplastic activity. Parsatuzumab binds to EGFL7, thereby preventing the activities of EGFL7 on endothelial cells and inhibiting the survival and migration of endothelial cells during angiogenesis. EGFL7, a vascular-restricted extracellular matrix protein which is upregulated during angiogenesis and which regulates vascular development, may be overexpressed on the cell surfaces of various solid tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"852693AD-C641-32F2-E040-BB89AD436CB9","latestVersionIndicator":"Yes","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F46B-77C5-E040-BB89AD437145","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Montelukast","valueDescription":"Montelukast Sodium (Singulair)","ValueMeaning":{"publicId":"2578304","version":"1","preferredName":"Montelukast Sodium (Singulair)","longName":"2578304","preferredDefinition":"The monosodium salt of montelukast, a selective and orally active leukotriene receptor antagonist with anti-inflammatory and bronchodilator activity. Montelukast sodium selectively and competitively blocks the cysteinyl leukotriene 1 (CysLT1) receptor, thereby preventing leukotriene D4 from binding to its receptor. This prevents leukotriene-mediated activities, including enhanced migration of eosinophils and neutrophils, increased adhesion of leukocytes, increased monocyte and neutrophil aggregation, increased airway edema, increased capillary permeability and bronchoconstriction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Montelukast Sodium","conceptCode":"C47625","definition":"The orally bioavailable monosodium salt of montelukast, a selective cysteinyl leukotriene receptor antagonist with anti-inflammatory and bronchodilating activities. Montelukast selectively and competitively blocks the cysteinyl leukotriene 1 (CysLT1) receptor, preventing binding of the inflammatory mediator leukotriene D4 (LTD4). Inhibition of LTD4 activity results in inhibition of leukotriene-mediated inflammatory events including: migration of eosinophils and neutrophils; adhesion of leukocytes to vascular endothelium, monocyte and neutrophil aggregation; increased airway edema; increased capillary permeability; and bronchoconstriction. The CysLT1 receptor is found in a number of tissues including spleen, lung, placenta, small intestine, and nasal mucosa, and in a variety of cell types including monocyte/macrophages, mast cells, eosinophils, CD34-positive hemopoietic progenitor cells, neutrophils and endothelial cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEED-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"REEVESD","dateModified":"2010-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F475-77C5-E040-BB89AD437145","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"NY-ESO-1 Peptide Vaccine","valueDescription":"NY-ESO-1 Peptide Vaccine","ValueMeaning":{"publicId":"3061104","version":"1","preferredName":"NY-ESO-1 Peptide Vaccine","longName":"3061104","preferredDefinition":"A cancer vaccine consisting of an immunogenic peptide derived from the cancer-testis antigen (NY-ESO-1), an antigen found in normal testis and various tumors. Vaccination with NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response to cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NY-ESO-1 Peptide Vaccine","conceptCode":"C2657","definition":"A cancer vaccine consisting of an immunogenic peptide derived from the cancer-testis antigen (NY-ESO-1), an antigen found in normal testis and various tumors. Vaccination with NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response to cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8448DBD5-814E-B470-E040-BB89AD433DC3","latestVersionIndicator":"Yes","beginDate":"2010-04-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F47F-77C5-E040-BB89AD437145","beginDate":"2010-04-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Oxandrolone","valueDescription":"Oxandrolone (Oxandrin)","ValueMeaning":{"publicId":"3076461","version":"1","preferredName":"Oxandrolone (Oxandrin)","longName":"3076461","preferredDefinition":"A synthetic, anabolic steroid hormone analog of testosterone. Similar to testosterone, oxandrolone binds to and activates specific nuclear receptors. This agent may be used for testosterone replacement therapy in hypogonadal men, in HIV-wasting syndrome, and in other conditions in order to increase nitrogen retention and fat-free muscle mass. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxandrolone","conceptCode":"C29306","definition":"A synthetic, anabolic steroid hormone analog of testosterone. Similar to testosterone, oxandrolone binds to and activates specific nuclear receptors. This agent may be used for testosterone replacement therapy in hypogonadal men, in HIV-wasting syndrome, and in other conditions in order to increase nitrogen retention and fat-free muscle mass. (NCI04)","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"852693AD-C7A9-32F2-E040-BB89AD436CB9","latestVersionIndicator":"Yes","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F489-77C5-E040-BB89AD437145","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"PG13-CEA_TCR","valueDescription":"PG13-CEA_TCR","ValueMeaning":{"publicId":"3021177","version":"1","preferredName":"PG13-CEA_TCR","longName":"3021177","preferredDefinition":"PG13-CEA_TCR","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"817312F9-59D6-37DB-E040-BB89AD437AE8","latestVersionIndicator":"Yes","beginDate":"2010-03-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F493-77C5-E040-BB89AD437145","beginDate":"2010-03-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Pulmicort","valueDescription":"Budesonide","ValueMeaning":{"publicId":"2576032","version":"1","preferredName":"Budesonide","longName":"2576032","preferredDefinition":"A glucocorticoid used in the management of asthma, the treatment of various skin disorders, and allergic rhinitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Budesonide","conceptCode":"C1027","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon administration, budesonide binds to intracellular glucocorticoid receptors (GRs) and induces the expression of glucocorticoid-responsive genes that encode for anti-inflammatory mediators, such as certain anti-inflammatory cytokines, including interleukin 10 (IL-10), and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, budesonide prevents the release of pro-inflammatory cytokines from epithelial cells and macrophages, including interleukin 6 (IL-6), IL-8, interferon-beta (IFNb), and inhibits nuclear factor kappa-B (NF-kB) activation thereby decreasing NF-kB-mediated inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F60D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2012-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F49D-77C5-E040-BB89AD437145","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Reolysin","valueDescription":"Reolysin","ValueMeaning":{"publicId":"3124280","version":"1","preferredName":"Reolysin","longName":"3124280","preferredDefinition":"A serotype 3 Dearing strain (T3D) of reovirus (Respiratory Enteric Orphan VIRUS). Reovirus, a dsRNA virus, is able to replicate specifically in cancer cells bearing an activated Ras pathway. In contrast to normal cells, two-thirds of human cancer cells are Ras-activated, and are deficient in their ability to trigger the antiviral response mediated by the host cellular protein, double-stranded RNA-dependent protein kinase (PKR). In Ras-activated cancer cells, reovirus is able to freely replicate and subsequently cause apoptosis in the tumor cells. Cell lysis frees progeny viral particles to infect surrounding cancer cells. This cycle of infection, replication and cell death is believed to be repeated until no more Ras-activated tumor cells are available. Because the reovirus kills Ras-activated cancer cells, this is a potential therapeutic for malignant glioma, pancreatic, colon and some lung cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pelareorep","conceptCode":"C60774","definition":"An isolate of the oncolytic, human wild-type serotype 3 Dearing (T3D) strain of the double-stranded RNA virus reovirus (Respiratory Enteric Orphan virus), with potential oncolytic activity. Upon administration, pelareorep is able to replicate specifically in cancer cells bearing an activated Ras pathway. This induces apoptosis in Ras-activated tumor cells and subsequently frees progeny viral particles to infect, replicate in and induce cell death of surrounding cancer cells. In addition, viral replication causes the activation of innate and adaptive immune responses, causing a natural killer (NK)-cell-mediated and a cytotoxic T-cell (CTL)-mediated killing of tumor cells, respectively. Ras-activated tumor cells are deficient in their ability to trigger the antiviral response mediated by the host cellular protein, double-stranded RNA-dependent protein kinase (PKR).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C0EAA9F-D646-4F99-E040-BB89AD435CFD","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F4A7-77C5-E040-BB89AD437145","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Technetium Tc-99m Apcitide","valueDescription":"Technetium Tc-99m Apcitide","ValueMeaning":{"publicId":"2939364","version":"1","preferredName":"Technetium Tc-99m Apcitide","longName":"2939364","preferredDefinition":"A radioconjugate comprised of the small peptide apcitide labeled with the gamma-emitting technetium TC99m (metastable Tc-99). Apcitide binds to platelet glycoprotein (GP) GPIIb/IIIa receptors on the surface of activated platelets. Labeling apcitide with TC99m allows localization of thrombus formation by gamma-ray imaging equipment and the ability to distinguish between old, inactive thrombi and new, active thrombi.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Technetium Tc-99m Apcitide","conceptCode":"C47745","definition":"A radioconjugate comprised of the small peptide apcitide labeled with the gamma-emitting technetium TC99m (metastable Tc-99). Apcitide binds to platelet glycoprotein (GP) GPIIb/IIIa receptors on the surface of activated platelets. Labeling apcitide with TC99m allows localization of thrombus formation by gamma-ray imaging equipment and the ability to distinguish between old, inactive thrombi and new, active thrombi.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7339449B-3976-92A9-E040-BB89AD435E25","latestVersionIndicator":"Yes","beginDate":"2009-09-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F4B1-77C5-E040-BB89AD437145","beginDate":"2009-09-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Tiotropium","valueDescription":"Tiotropium Bromide Monohydrate","ValueMeaning":{"publicId":"3076452","version":"1","preferredName":"Tiotropium Bromide Monohydrate","longName":"3076452v1.00","preferredDefinition":"The monohydrate bromide salt form of tiotropium, a quaternary ammonium derivative of atropine and a long-acting muscarinic receptor antagonist, with bronchodilating activity. Upon inhalation, tiotropium binds to and blocks mainly muscarinic M3 receptors located on smooth muscle cells, thereby preventing smooth muscle contraction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tiotropium Bromide Monohydrate","conceptCode":"C61974","definition":"The monohydrate bromide salt form of tiotropium, a quaternary ammonium derivative of atropine and a long-acting muscarinic receptor antagonist, with bronchodilating activity. Upon inhalation, tiotropium binds to and blocks mainly muscarinic M3 receptors located on smooth muscle cells, thereby preventing smooth muscle contraction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"852693AD-C6DB-32F2-E040-BB89AD436CB9","latestVersionIndicator":"Yes","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F4BB-77C5-E040-BB89AD437145","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"TRICOM","valueDescription":"TRICOM","ValueMeaning":{"publicId":"3013193","version":"1","preferredName":"TRICOM","longName":"3013193","preferredDefinition":"TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3).  An immunostimulant.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"TRICOM","conceptCode":"C2192","definition":"TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3).  An immunostimulant.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FF9397D-428B-21AE-E040-BB89AD436688","latestVersionIndicator":"Yes","beginDate":"2010-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CEC9CF9-F4C5-77C5-E040-BB89AD437145","beginDate":"2010-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","deletedIndicator":"No"},{"value":"Bendamustine","valueDescription":"Bendamustine (Ribomustin, Treanda, SDX-105)","ValueMeaning":{"publicId":"3143776","version":"1","preferredName":"Bendamustine (Ribomustin, Treanda, SDX-105)","longName":"3143776v1.00","preferredDefinition":"A bifunctional mechlorethamine derivative with alkylating and antimetabolite activities. Although the exact mechanism of action of bendamustine is unknown, this agent appears to alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and eventually the induction of apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bendamustine","conceptCode":"C73261","definition":"A bifunctional mechlorethamine derivative with alkylating and antimetabolite activities. Although the exact mechanism of action of bendamustine is unknown, this agent appears to alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and eventually the induction of apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"916763D9-5D31-609F-E040-BB89AD437013","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-29","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"916763D9-5D4A-609F-E040-BB89AD437013","beginDate":"2010-09-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-29","modifiedBy":"ONEDATA","dateModified":"2010-09-29","deletedIndicator":"No"},{"value":"Ofatumumab","valueDescription":"Ofatumumab","ValueMeaning":{"publicId":"3243442","version":"1","preferredName":"Ofatumumab","longName":"3243442","preferredDefinition":"A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ofatumumab","conceptCode":"C66952","definition":"A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A55A32E7-3256-D7C0-E040-BB89AD437508","latestVersionIndicator":"Yes","beginDate":"2011-06-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A55A32E7-326F-D7C0-E040-BB89AD437508","beginDate":"2011-06-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-06-10","modifiedBy":"ONEDATA","dateModified":"2011-06-10","deletedIndicator":"No"},{"value":"Vemurafenib","valueDescription":"Vemurafenib","ValueMeaning":{"publicId":"3422122","version":"1","preferredName":"Vemurafenib","longName":"3422122","preferredDefinition":"An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vemurafenib","conceptCode":"C64768","definition":"An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC3ACCEE-3440-DAF6-E040-BB89AD433B37","latestVersionIndicator":"Yes","beginDate":"2012-03-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-27","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC3ACCEE-3459-DAF6-E040-BB89AD433B37","beginDate":"2012-03-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-27","modifiedBy":"ONEDATA","dateModified":"2012-03-27","deletedIndicator":"No"},{"value":"Pimecrolimus","valueDescription":"Pimecrolimus","ValueMeaning":{"publicId":"3624677","version":"1","preferredName":"Pimecrolimus","longName":"3624677","preferredDefinition":"A 33-epi-chloro-derivative of the ascomycin macrolactam with immunosuppressant property. Pimecrolimus binds to the receptor macrophilin-12 (FKBP-12) forming a complex that blocks the calcium-dependent signal transduction cascade mediated by calcineurin. Via dephosphorylation, calcineurin is the enzyme responsible for activating nuclear factor of activated T-cells (NF-AT), a T cell transcriptional regulatory factor. As a consequence, the synthesis and release of Th1- (T helper 1) and Th2- (T helper 2) type cytokines, and other inflammatory mediators from T-cells and mast cells are blocked and the expression of signals essential for the activation of inflammatory T-lymphocytes is inhibited. However, pimecrolimus mode of action is cell-selective and does not affect Langerhans' cells/dendritic cells and primary fibroblasts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pimecrolimus","conceptCode":"C47671","definition":"A 33-epi-chloro-derivative of the ascomycin macrolactam with immunosuppressant property. Pimecrolimus binds to the receptor macrophilin-12 (FKBP-12) forming a complex that blocks the calcium-dependent signal transduction cascade mediated by calcineurin. Via dephosphorylation, calcineurin is the enzyme responsible for activating nuclear factor of activated T-cells (NF-AT), a T cell transcriptional regulatory factor. As a consequence, the synthesis and release of Th1- (T helper 1) and Th2- (T helper 2) type cytokines, and other inflammatory mediators from T-cells and mast cells are blocked and the expression of signals essential for the activation of inflammatory T-lymphocytes is inhibited. However, pimecrolimus mode of action is cell-selective and does not affect Langerhans' cells/dendritic cells and primary fibroblasts.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CD82BCC0-11EF-B6BC-E040-BB89AD431513","latestVersionIndicator":"Yes","beginDate":"2012-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CD82BCC0-1208-B6BC-E040-BB89AD431513","beginDate":"2012-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-02","modifiedBy":"ONEDATA","dateModified":"2012-11-02","deletedIndicator":"No"},{"value":"Beclomethasone","valueDescription":"Beclomethasone","ValueMeaning":{"publicId":"3624679","version":"1","preferredName":"Beclomethasone","longName":"3624679","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Beclomethasone","conceptCode":"C62009","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CD82BCC0-1215-B6BC-E040-BB89AD431513","latestVersionIndicator":"Yes","beginDate":"2012-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CD82BCC0-122E-B6BC-E040-BB89AD431513","beginDate":"2012-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-02","modifiedBy":"ONEDATA","dateModified":"2012-11-02","deletedIndicator":"No"},{"value":"Cyclosporine Ophthalmic Emulsion","valueDescription":"Cyclosporine Ophthalmic Emulsion","ValueMeaning":{"publicId":"3564172","version":"1","preferredName":"Cyclosporine Ophthalmic Emulsion","longName":"3564172","preferredDefinition":"An topical ophthalmic formulation containing cyclosporine, an undecapeptide produced by the fungus Beauveria nivea, with immunosuppressant and anti-inflammatory activities. The exact therapeutic mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclosporine Ophthalmic Emulsion","conceptCode":"C80051","definition":"An topical ophthalmic formulation containing cyclosporine, an undecapeptide produced by the fungus Beauveria nivea, with immunosuppressant and anti-inflammatory activities. The exact therapeutic mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7DE3983-D865-00EE-E040-BB89AD432ACB","latestVersionIndicator":"Yes","beginDate":"2012-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CD82BCC0-1242-B6BC-E040-BB89AD431513","beginDate":"2012-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-02","modifiedBy":"ONEDATA","dateModified":"2012-11-02","deletedIndicator":"No"},{"value":"Carboxymethylcellulose","valueDescription":"Carboxymethylcellulose","ValueMeaning":{"publicId":"3624681","version":"1","preferredName":"Carboxymethylcellulose","longName":"3624681v1.00","preferredDefinition":"A polymer and cellulose derivative that can be used as a viscosity modifier and thickener to stabilize emulsions. In medical products, carboxymethylcellulose is used as a lubricating agent in artificial tears and in wound dressings to improve wound healing.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboxymethylcellulose","conceptCode":"C83594","definition":"A polymer and cellulose derivative that can be used as a viscosity modifier and thickener to stabilize emulsions. In medical products, carboxymethylcellulose is used as a lubricating agent in artificial tears and in wound dressings to improve wound healing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CD82BCC0-124F-B6BC-E040-BB89AD431513","latestVersionIndicator":"Yes","beginDate":"2012-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-02","modifiedBy":"KUMMEROA","dateModified":"2023-09-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CD82BCC0-1267-B6BC-E040-BB89AD431513","beginDate":"2012-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-02","modifiedBy":"ONEDATA","dateModified":"2012-11-02","deletedIndicator":"No"},{"value":"Clobetasol","valueDescription":"Clobetasol","ValueMeaning":{"publicId":"3624683","version":"1","preferredName":"Clobetasol","longName":"3624683v1.00","preferredDefinition":"A topical synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Upon topical administration, clobetasol binds to cytoplasmic glucocorticoid receptors (GRs) and activates GR-mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol induces phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2. This inhibits skin inflammation, and reduces swelling, redness, itching and rashes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clobetasol","conceptCode":"C65339","definition":"A topical synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Upon topical administration, clobetasol binds to cytoplasmic glucocorticoid receptors (GRs) and activates GR-mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol induces phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2. This inhibits skin inflammation, and reduces swelling, redness, itching and rashes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CD82BCC0-1275-B6BC-E040-BB89AD431513","latestVersionIndicator":"Yes","beginDate":"2012-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-02","modifiedBy":"KUMMEROA","dateModified":"2023-09-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CD82BCC0-128E-B6BC-E040-BB89AD431513","beginDate":"2012-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-02","modifiedBy":"ONEDATA","dateModified":"2012-11-02","deletedIndicator":"No"},{"value":"Triamcinolone","valueDescription":"Triamcinolone","ValueMeaning":{"publicId":"3305278","version":"1","preferredName":"Triamcinolone","longName":"3305278","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon cell entry, triamcinolone binds to and activates the glucocorticoid receptor, which leads to translocation of the ligand-receptor complex to the nucleus and induces expression of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, pro-inflammatory cytokine production, including interleukin (IL)-1and IL-6, and the activation of cytotoxic T-lymphocytes is also inhibited. T-cells are prevented from making IL-2 and proliferating. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis through increasing Ikappa-B expression and curtailing activation of nuclear factor (NF)kappa-B.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Triamcinolone","conceptCode":"C901","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon cell entry, triamcinolone binds to and activates the glucocorticoid receptor, which leads to translocation of the ligand-receptor complex to the nucleus and induces expression of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, pro-inflammatory cytokine production, including interleukin (IL)-1and IL-6, and the activation of cytotoxic T-lymphocytes is also inhibited. T-cells are prevented from making IL-2 and proliferating. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis through increasing Ikappa-B expression and curtailing activation of nuclear factor (NF)kappa-B.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1A4B8-0D8C-8518-E040-BB89AD435A01","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CD82BCC0-1298-B6BC-E040-BB89AD431513","beginDate":"2012-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-02","modifiedBy":"ONEDATA","dateModified":"2012-11-02","deletedIndicator":"No"},{"value":"Flucinolone","valueDescription":"Flucinolone","ValueMeaning":{"publicId":"2576861","version":"1","preferredName":"Flucinolone","longName":"2576861v1.00","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and antipruritic activities. Fluocinolone binds the glucocorticoid receptor, followed by translocation of the ligand-receptor complex to the nucleus and transcription activation of genes containing glucocorticoid-responsive elements. Lipocortin-1 is one factor induced by fluocinolone that interacts with and inhibits cytosolic phospholipase 2 alpha, thereby preventing phospholipase translocation to the perinuclear membrane and subsequent release and conversion of arachidonic acid to inflammatory prostaglandins. In addition, MAPK phosphatase 1 is induced, thereby preventing the triggering of the MAPK cascade resulting in pro-inflammatory effects via Jun N-terminal kinase and c-Jun. Finally, fluocinolone binds to and inhibits nuclear factor kappa-B directly, resulting in inhibition of cyclooxygenase 2 transcription and subsequent prostaglandin synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluocinolone","conceptCode":"C29053","definition":"A synthetic glucocorticoid with anti-inflammatory and antipruritic activities. Fluocinolone binds the glucocorticoid receptor, followed by translocation of the ligand-receptor complex to the nucleus and transcription activation of genes containing glucocorticoid-responsive elements. Lipocortin-1 is one factor induced by fluocinolone that interacts with and inhibits cytosolic phospholipase 2 alpha, thereby preventing phospholipase translocation to the perinuclear membrane and subsequent release and conversion of arachidonic acid to inflammatory prostaglandins. In addition, MAPK phosphatase 1 is induced, thereby preventing the triggering of the MAPK cascade resulting in pro-inflammatory effects via Jun N-terminal kinase and c-Jun. Finally, fluocinolone binds to and inhibits nuclear factor kappa-B directly, resulting in inhibition of cyclooxygenase 2 transcription and subsequent prostaglandin synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F94A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CD82BCC0-12A2-B6BC-E040-BB89AD431513","beginDate":"2012-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-02","modifiedBy":"ONEDATA","dateModified":"2012-11-02","deletedIndicator":"No"},{"value":"LDK378","valueDescription":"ALK inhibitor LDK378","ValueMeaning":{"publicId":"3595598","version":"1","preferredName":"ALK inhibitor LDK378","longName":"3595598v1.00","preferredDefinition":"An orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ceritinib","conceptCode":"C115112","definition":"An orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA68E09A-F73D-E0A9-E040-BB89AD4338DB","latestVersionIndicator":"Yes","beginDate":"2012-09-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-23","modifiedBy":"KUMMEROA","dateModified":"2023-09-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CA68E09A-F756-E0A9-E040-BB89AD4338DB","beginDate":"2012-09-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-23","modifiedBy":"ONEDATA","dateModified":"2012-09-23","deletedIndicator":"No"},{"value":"Thalidomide","valueDescription":"Thalidomide","ValueMeaning":{"publicId":"3253641","version":"1","preferredName":"Thalidomide","longName":"3253641","preferredDefinition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  Thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thalidomide","conceptCode":"C870","definition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A81EFF99-79AE-7C87-E040-BB89AD430597","latestVersionIndicator":"Yes","beginDate":"2011-07-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-07-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DD33D016-58DA-8C70-E040-BB89AD432AB2","beginDate":"2013-05-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-05-21","modifiedBy":"ONEDATA","dateModified":"2013-05-21","deletedIndicator":"No"},{"value":"Budesonide","valueDescription":"Budesonide","ValueMeaning":{"publicId":"2576032","version":"1","preferredName":"Budesonide","longName":"2576032","preferredDefinition":"A glucocorticoid used in the management of asthma, the treatment of various skin disorders, and allergic rhinitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Budesonide","conceptCode":"C1027","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon administration, budesonide binds to intracellular glucocorticoid receptors (GRs) and induces the expression of glucocorticoid-responsive genes that encode for anti-inflammatory mediators, such as certain anti-inflammatory cytokines, including interleukin 10 (IL-10), and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, budesonide prevents the release of pro-inflammatory cytokines from epithelial cells and macrophages, including interleukin 6 (IL-6), IL-8, interferon-beta (IFNb), and inhibits nuclear factor kappa-B (NF-kB) activation thereby decreasing NF-kB-mediated inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F60D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2012-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D38F2894-810F-1E17-E040-BB89AD432177","beginDate":"2013-01-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-18","modifiedBy":"ONEDATA","dateModified":"2013-01-18","deletedIndicator":"No"},{"value":"Busulfan","valueDescription":"Busulfan","ValueMeaning":{"publicId":"2739539","version":"1","preferredName":"Busulfan","longName":"2739539","preferredDefinition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Busulfan","conceptCode":"C321","definition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BBD0-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA9C47AB-B638-7564-E040-BB89AD437320","beginDate":"2013-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-07","modifiedBy":"ONEDATA","dateModified":"2013-11-07","deletedIndicator":"No"},{"value":"Idelalisib","valueDescription":"Idelalisib","ValueMeaning":{"publicId":"5096863","version":"1","preferredName":"Idelalisib","longName":"5096863","preferredDefinition":"An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.  Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idelalisib","conceptCode":"C78825","definition":"An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.  Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28ACEAFB-479D-6667-E050-BB89AD432DA7","latestVersionIndicator":"Yes","beginDate":"2016-01-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-01-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"28ACEAFB-47B6-6667-E050-BB89AD432DA7","beginDate":"2016-01-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-01-06","modifiedBy":"ONEDATA","dateModified":"2016-01-06","deletedIndicator":"No"},{"value":"DCI","valueDescription":"Donor Cellular Infusion","ValueMeaning":{"publicId":"4926573","version":"1","preferredName":"Donor Cellular Infusion","longName":"4926573","preferredDefinition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Donor Cellular Infusion","conceptCode":"C77273","definition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1C69AAD8-76B5-DEDC-E050-BB89AD434FD9","latestVersionIndicator":"Yes","beginDate":"2015-08-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-08-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1F3B49CE-A0D7-F479-E050-BB89AD437DA3","beginDate":"2015-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-09-08","modifiedBy":"ONEDATA","dateModified":"2015-09-08","deletedIndicator":"No"},{"value":"DLI","valueDescription":"Donor Leukocyte Infusion","ValueMeaning":{"publicId":"2866902","version":"1","preferredName":"Donor Leukocyte Infusion","longName":"2866902","preferredDefinition":"A type of therapy in which lymphocytes from the blood of a donor are given to a patient who has already received a stem cell transplant from the same donor. The donor lymphocytes may kill remaining cancer cells. Donor lymphocyte infusion is used to treat chronic myelogenous leukemia (CML) that has come back and myeloma. It is being studied in the treatment of other types of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Donor Lymphocyte Infusion","conceptCode":"C16145","definition":"The infusion of donor lymphocytes following hematopoietic stem cell transplantation for the purpose of augmenting the host immune response or preventing the rejection of the graft.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68DF7602-9A6D-3F9A-E040-BB89AD43599F","latestVersionIndicator":"Yes","beginDate":"2009-05-01","endDate":null,"createdBy":"CZECHS","dateCreated":"2009-05-01","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1F3B49CE-A0EB-F479-E050-BB89AD437DA3","beginDate":"2015-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-09-08","modifiedBy":"ONEDATA","dateModified":"2015-09-08","deletedIndicator":"No"},{"value":"Ruxolitinib","valueDescription":"Ruxolitinib","ValueMeaning":{"publicId":"5125106","version":"1","preferredName":"Ruxolitinib","longName":"5125106","preferredDefinition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ruxolitinib","conceptCode":"C77888","definition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C0D42D8-A87E-AEAF-E050-BB89AD430679","latestVersionIndicator":"Yes","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"33C14C60-FD58-8233-E050-BB89AD433B3A","beginDate":"2016-05-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-26","modifiedBy":"ONEDATA","dateModified":"2016-05-26","deletedIndicator":"No"},{"value":"Nivolumab","valueDescription":"Nivolumab","ValueMeaning":{"publicId":"5076694","version":"1","preferredName":"Nivolumab","longName":"5076694","preferredDefinition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nivolumab","conceptCode":"C68814","definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EBB8-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AECAE5-BCD2-28A7-E053-F662850AD609","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Tocilizumab","valueDescription":"Tocilizumab","ValueMeaning":{"publicId":"4618052","version":"1","preferredName":"Tocilizumab","longName":"4618052","preferredDefinition":"A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. Il-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders and certain types of cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tocilizumab","conceptCode":"C84217","definition":"A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0953B289-65BB-6299-E050-BB89AD4328C8","latestVersionIndicator":"Yes","beginDate":"2014-12-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-12-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AECAE5-BCE6-28A7-E053-F662850AD609","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Siltuximab","valueDescription":"Siltuximab","ValueMeaning":{"publicId":"5621734","version":"1","preferredName":"Siltuximab","longName":"5621734","preferredDefinition":"A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Siltuximab","conceptCode":"C61084","definition":"A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BCF0-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AECAE5-BD09-28A7-E053-F662850AD609","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Oxaliplatin","valueDescription":"Oxaliplatin","ValueMeaning":{"publicId":"2579327","version":"1","preferredName":"Oxaliplatin","longName":"2579327","preferredDefinition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxaliplatin","conceptCode":"C1181","definition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-02EC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"REEVESD","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AECAE5-BD1D-28A7-E053-F662850AD609","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":":  CD19 CAR T-cells","valueDescription":"CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes","ValueMeaning":{"publicId":"5621736","version":"1","preferredName":"CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes","longName":"5621736","preferredDefinition":"Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, CD19CAR-CD3zeta-4-1BB-expressing autologous T-lymphocytes direct the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3-zeta (or CD247) is a transmembrane signaling adaptor polypeptide that regulates the assembly of complete TCR complexes and their expression on the cell surface.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tisagenlecleucel","conceptCode":"C102758","definition":"Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, tisagenlecleucel directs the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3-zeta (or CD247) is a transmembrane signaling adaptor polypeptide that regulates the assembly of complete TCR complexes and their expression on the cell surface.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BD2A-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AECAE5-BD43-28A7-E053-F662850AD609","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Pegaspargase","valueDescription":"Pegaspargase","ValueMeaning":{"publicId":"3379428","version":"1","preferredName":"Pegaspargase","longName":"3379428","preferredDefinition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegaspargase","conceptCode":"C1200","definition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2066-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"KUMMEROA","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AECAE5-BD57-28A7-E053-F662850AD609","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Decitabine","valueDescription":"Decitabine","ValueMeaning":{"publicId":"2577852","version":"1","preferredName":"Decitabine","longName":"2577852","preferredDefinition":"A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Decitabine","conceptCode":"C981","definition":"A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD29-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AECAE5-BD6B-28A7-E053-F662850AD609","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Sorafenib","valueDescription":"Sorafenib","ValueMeaning":{"publicId":"3380164","version":"1","preferredName":"Sorafenib","longName":"3380164","preferredDefinition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sorafenib","conceptCode":"C61948","definition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A2A6B-9613-1351-E040-BB89AD432684","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AECAE5-BD7F-28A7-E053-F662850AD609","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"CXD101","valueDescription":"HDAC Inhibitor CXD101","ValueMeaning":{"publicId":"5621738","version":"1","preferredName":"HDAC Inhibitor CXD101","longName":"5621738","preferredDefinition":"A novel histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Although the exact therapeutic mechanism of action for CXD101 is not known, oral administration of this agent should inhibit the catalytic activity of HDAC, which results in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. HDAC, a family of enzymes upregulated in many tumor types, deacetylates chromatin-associated histone proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zabadinostat","conceptCode":"C112177","definition":"A novel histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Although the exact therapeutic mechanism of action for CXD101 is not known, oral administration of this agent should inhibit the catalytic activity of HDAC, which results in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. HDAC, a family of enzymes upregulated in many tumor types, deacetylates chromatin-associated histone proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BD8C-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AECAE5-BDA5-28A7-E053-F662850AD609","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Ponatinib","valueDescription":"Ponatinib","ValueMeaning":{"publicId":"3776076","version":"1","preferredName":"Ponatinib","longName":"3776076","preferredDefinition":"An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ponatinib","conceptCode":"C95777","definition":"An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE84372B-DC57-3F77-E040-BB89AD432E57","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"45AECAE5-BDB9-28A7-E053-F662850AD609","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"ONEDATA","dateModified":"2017-01-09","deletedIndicator":"No"},{"value":"Copanlisib","valueDescription":null,"ValueMeaning":{"publicId":"12117784","version":"1","preferredName":"Copanlisib Hydrochloride (Aliqopa)","longName":"12117784v1.00","preferredDefinition":"The dihydrochloride salt form of copanlisib, a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Copanlisib Hydrochloride","conceptCode":"C138994","definition":"The dihydrochloride salt form of copanlisib, a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEA771CA-4F81-4CFD-E053-731AD00A43EC","latestVersionIndicator":"Yes","beginDate":"2022-11-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-29","modifiedBy":"GDEEN","dateModified":"2022-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EF1E19C7-E2BF-3037-E053-731AD00A23D6","beginDate":"2022-12-05","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-05","modifiedBy":"GDEEN","dateModified":"2022-12-05","deletedIndicator":"No"},{"value":"Vortioxetine Hydrobromide","valueDescription":null,"ValueMeaning":{"publicId":"12127874","version":"1","preferredName":"Vortioxetine Hydrobromide (Trintellix)","longName":"12127874v1.00","preferredDefinition":"A hydrobromide salt form of vortioxetine, a serotonin (5-HT) modulator and stimulator (SMS), with antidepressant activity. Vortioxetine inhibits the reuptake of serotonin and norepinephrine from the synaptic cleft and acts variably as a serotonin receptor agonist (5-HT1A), partial agonist (5-HT1B) or antagonist (5-HT3, 5-HT1D and 5-HT7). It is not clear how this agent's purported multimodal mechanism of action contributes to its antidepressant effect; however, it is presumed to increase the synaptic availability of serotonin and norepinephrine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vortioxetine Hydrobromide","conceptCode":"C125653","definition":"A hydrobromide salt form of vortioxetine, a serotonin (5-HT) modulator and stimulator (SMS), with antidepressant activity. Vortioxetine inhibits the reuptake of serotonin and norepinephrine from the synaptic cleft and acts variably as a serotonin receptor agonist (5-HT1A), partial agonist (5-HT1B) or antagonist (5-HT3, 5-HT1D and 5-HT7). It is not clear how this agent's purported multimodal mechanism of action contributes to its antidepressant effect; however, it is presumed to increase the synaptic availability of serotonin and norepinephrine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF354FFA-1174-5D37-E053-731AD00AFA66","latestVersionIndicator":"Yes","beginDate":"2022-12-06","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-06","modifiedBy":"GDEEN","dateModified":"2022-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EF3F591B-BAD8-10BB-E053-731AD00A04E7","beginDate":"2022-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-07","modifiedBy":"GDEEN","dateModified":"2022-12-07","deletedIndicator":"No"},{"value":"Polyethylene Glycol 400/Propylene Glycol-containing Eye Drop","valueDescription":null,"ValueMeaning":{"publicId":"12173256","version":"1","preferredName":"Polyethylene Glycol 400/Propylene Glycol-containing Eye Drop (Systane)","longName":"12173256v1.00","preferredDefinition":"An eye drop solution containing polyethylene glycol (PEG) 400 and propylene glycol used for the relief of dry eye. Upon application of the drops into the eye, PEG 400 and propylene glycol lubricate the eye and relieve dryness and irritation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polyethylene Glycol 400/Propylene Glycol-containing Eye Drop","conceptCode":"C191779","definition":"An eye drop solution containing polyethylene glycol (PEG) 400 and propylene glycol used for the relief of dry eye. Upon application of the drops into the eye, PEG 400 and propylene glycol lubricate the eye and relieve dryness and irritation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F032E55A-3C26-2E85-E053-731AD00A95DF","latestVersionIndicator":"Yes","beginDate":"2022-12-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-19","modifiedBy":"GDEEN","dateModified":"2022-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F033022B-40AB-3C5B-E053-731AD00A843D","beginDate":"2022-12-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-19","modifiedBy":"GDEEN","dateModified":"2022-12-19","deletedIndicator":"No"},{"value":"Carboxymethylcellulose Sodium-containing Eye Drop","valueDescription":null,"ValueMeaning":{"publicId":"3777004","version":"1","preferredName":"Carboxymethylcellulose Sodium-containing Eye Drop","longName":"3777004","preferredDefinition":"An eye drop solution containing the sodium salt form of carboxymethylcellulose (CMC) used as artificial tears. Upon application of the drops into the eye, carboxymethylcellulose sodium lubricates the eye and prevents or relieves dryness and irritation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboxymethylcellulose Sodium-containing Eye Drop","conceptCode":"C106410","definition":"An eye drop solution containing the sodium salt form of carboxymethylcellulose (CMC) used as artificial tears. Upon application of the drops into the eye, carboxymethylcellulose sodium lubricates the eye and prevents or relieves dryness and irritation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DECE2246-538B-B502-E040-BB89AD4311C4","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-10","modifiedBy":"GDEEN","dateModified":"2022-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F033022B-40AC-3C5B-E053-731AD00A843D","beginDate":"2022-12-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-19","modifiedBy":"GDEEN","dateModified":"2022-12-19","deletedIndicator":"No"},{"value":"Mepivacaine Hydrochloride","valueDescription":null,"ValueMeaning":{"publicId":"12267130","version":"1","preferredName":"Mepivacaine Hydrochloride (Carbocaine)","longName":"12267130v1.00","preferredDefinition":"The hydrochloride salt form of mepivacaine, an amide derivative with local anesthetic properties.  At the injection site, mepivacaine hydrochloride acts by binding to specific membrane sodium ion channels in the neuronal cell membranes, thereby inhibiting sodium influx. This leads to a blockage of nerve impulse conduction and results in a loss of sensation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mepivacaine Hydrochloride","conceptCode":"C47602","definition":"The hydrochloride salt form of mepivacaine, an amide derivative with local anesthetic properties.  At the injection site, mepivacaine hydrochloride acts by binding to specific membrane sodium ion channels in the neuronal cell membranes, thereby inhibiting sodium influx. This leads to a blockage of nerve impulse conduction and results in a loss of sensation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F10F9205-BC32-2765-E053-731AD00A55C5","latestVersionIndicator":"Yes","beginDate":"2022-12-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-30","modifiedBy":"GDEEN","dateModified":"2022-12-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F10FABE1-F8E2-3277-E053-731AD00A7C96","beginDate":"2022-12-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-30","modifiedBy":"GDEEN","dateModified":"2022-12-30","deletedIndicator":"No"},{"value":"Vedolizumab","valueDescription":null,"ValueMeaning":{"publicId":"8115529","version":"1","preferredName":"Vedolizumab","longName":"8115529v1.00","preferredDefinition":"A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human lymphocyte Peyer's patch adhesion molecule 1 (LPAM-1; alpha4beta7; a4b7), with immunomodulating, anti-inflammatory, and potential antineoplastic activities. Upon administration, vedolizumab selectively binds to integrin a4b7 and prevents the binding of a4b7, expressed on the surface of a subset of T-lymphocytes, to its natural ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is mainly expressed on the surface of gut endothelial cells. This prevents a4b7-mediated signaling, adhesion of lymphocytes to the endothelium and the migration of T-lymphocytes across the endothelium into inflamed gastrointestinal (GI) tissue. By preventing this infiltration to the affected area, inflammation is reduced. The human lymphocyte a4b7 integrin, plays a key role in gastrointestinal (GI) inflammation; it is overexpressed in certain types of cancer cells. The alpha4beta7/MAdCAM-1 signaling pathway plays a critical role in the homing of T-lymphocytes to intestinal tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vedolizumab","conceptCode":"C95798","definition":"A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human lymphocyte Peyer's patch adhesion molecule 1 (LPAM-1; alpha4beta7; a4b7), with immunomodulating, anti-inflammatory, and potential antineoplastic activities. Upon administration, vedolizumab selectively binds to integrin a4b7 and prevents the binding of a4b7, expressed on the surface of a subset of T-lymphocytes, to its natural ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is mainly expressed on the surface of gut endothelial cells. This prevents a4b7-mediated signaling, adhesion of lymphocytes to the endothelium and the migration of T-lymphocytes across the endothelium into inflamed gastrointestinal (GI) tissue. By preventing this infiltration to the affected area, inflammation is reduced. The human lymphocyte a4b7 integrin, plays a key role in gastrointestinal (GI) inflammation; it is overexpressed in certain types of cancer cells. The alpha4beta7/MAdCAM-1 signaling pathway plays a critical role in the homing of T-lymphocytes to intestinal tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DAD1A896-3E8E-0376-E053-4EBD850A20B1","latestVersionIndicator":"Yes","beginDate":"2022-03-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-22","modifiedBy":"GDEEN","dateModified":"2023-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4123F5A-C486-4DD9-E053-731AD00A4871","beginDate":"2023-02-06","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-06","modifiedBy":"GDEEN","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"PRGN-2009","valueDescription":null,"ValueMeaning":{"publicId":"13966077","version":"1","preferredName":"Gorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 Vaccine","longName":"13966077v1.00","preferredDefinition":"An off-the-shelf (OTS) cancer vaccine comprised of a genetically engineered, replication-deficient gorilla-derived adenovirus encoding human papillomavirus (HPV) types 16 and 18 E6/E7 antigens, with potential immunostimulating and antineoplastic activities. Upon administration of gorilla-derived adenovirus expressing HPV-16/18 E6/E7 vaccine PRGN-2009, the adenovirus infects and expresses the HPV-16/18 E6/E7 proteins. The expressed proteins stimulate the host immune system to produce antigen-specific neutralizing antibodies and to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV-16/18 E6/E7 antigens, thereby inducing tumor cell lysis. HPV oncoproteins play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 Vaccine","conceptCode":"C172914","definition":"An off-the-shelf (OTS) cancer vaccine comprised of a genetically engineered, replication-deficient gorilla-derived adenovirus encoding human papillomavirus (HPV) types 16 and 18 E6/E7 antigens, with potential immunostimulating and antineoplastic activities. Upon administration of gorilla-derived adenovirus expressing HPV-16/18 E6/E7 vaccine PRGN-2009, the adenovirus infects and expresses the HPV-16/18 E6/E7 proteins. The expressed proteins stimulate the host immune system to produce antigen-specific neutralizing antibodies and to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV-16/18 E6/E7 antigens, thereby inducing tumor cell lysis. HPV oncoproteins play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEA99C1E-696B-78F2-E053-731AD00A730A","latestVersionIndicator":"Yes","beginDate":"2023-06-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-21","modifiedBy":"GDEEN","dateModified":"2023-06-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEA9B339-FA75-7B88-E053-731AD00A5931","beginDate":"2023-06-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-21","modifiedBy":"GDEEN","dateModified":"2023-06-21","deletedIndicator":"No"},{"value":"PRGN-2012","valueDescription":null,"ValueMeaning":{"publicId":"13966078","version":"1","preferredName":"Gorilla-derived Adenovirus-expressing HPV-6/11 Vaccine PRGN-2012","longName":"13966078v1.00","preferredDefinition":"An off-the-shelf (OTS) cancer vaccine comprised of a genetically engineered, replication-deficient gorilla-derived adenovirus encoding human papillomavirus (HPV) types 6 and 11, with potential immunostimulating and antineoplastic activities. Upon administration of gorilla-derived adenovirus-expressing HPV-6/11 vaccine PRGN-2012, the adenovirus infects and expresses the HPV-6/11 proteins. The expressed proteins stimulate the host immune system to produce antigen-specific neutralizing antibodies and to mount a cytotoxic T-lymphocyte (CTL) response against cells infected with HPV-6/11, thereby inducing tumor cell lysis. HPV6/11 play a key role in the development of recurrent respiratory papillomatosis (RRP).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gorilla-derived Adenovirus-expressing HPV-6/11 Vaccine PRGN-2012","conceptCode":"C177305","definition":"An off-the-shelf (OTS) cancer vaccine comprised of a genetically engineered, replication-deficient gorilla-derived adenovirus encoding human papillomavirus (HPV) types 6 and 11, with potential immunostimulating and antineoplastic activities. Upon administration of gorilla-derived adenovirus-expressing HPV-6/11 vaccine PRGN-2012, the adenovirus infects and expresses the HPV-6/11 proteins. The expressed proteins stimulate the host immune system to produce antigen-specific neutralizing antibodies and to mount a cytotoxic T-lymphocyte (CTL) response against cells infected with HPV-6/11, thereby inducing tumor cell lysis. HPV6/11 play a key role in the development of recurrent respiratory papillomatosis (RRP).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEA99C1E-696C-78F2-E053-731AD00A730A","latestVersionIndicator":"Yes","beginDate":"2023-06-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-21","modifiedBy":"GDEEN","dateModified":"2023-06-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FEA9B339-FA76-7B88-E053-731AD00A5931","beginDate":"2023-06-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-21","modifiedBy":"GDEEN","dateModified":"2023-06-21","deletedIndicator":"No"},{"value":"Lifitegrast","valueDescription":null,"ValueMeaning":{"publicId":"14059580","version":"1","preferredName":"Lifitegrast (Xiidra)","longName":"14059580v1.00","preferredDefinition":"A tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 (LFA-1) antagonist, that can be used as an ophthalmic solution for the treatment of dry eye disease (DED; keratoconjunctivitis sicca; dry eye syndrome). Upon ocular administration and although the exact mechanism of action of lifitegrast in DED is not fully known, lifitegrast targets and binds to the integrin LFA-1, a cell surface protein found on leukocytes. This prevents the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). As ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED, the blockage of the LFA-1/ICAM-1 interaction by lifitegrast may inhibit T-cell adhesion to ICAM-1 and may abrogate the formation of an immunological synapse. This may prevent T-cell proliferation, activation and migration and the release of pro-inflammatory cytokines in the corneal and conjunctival tissues. This may reduce inflammation, protect the corneal surface from inflammatory-mediated damage and reduce the symptoms of DED.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lifitegrast","conceptCode":"C175726","definition":"A tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 (LFA-1) antagonist, that can be used as an ophthalmic solution for the treatment of dry eye disease (DED; keratoconjunctivitis sicca; dry eye syndrome). Upon ocular administration and although the exact mechanism of action of lifitegrast in DED is not fully known, lifitegrast targets and binds to the integrin LFA-1, a cell surface protein found on leukocytes. This prevents the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). As ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED, the blockage of the LFA-1/ICAM-1 interaction by lifitegrast may inhibit T-cell adhesion to ICAM-1 and may abrogate the formation of an immunological synapse. This may prevent T-cell proliferation, activation and migration and the release of pro-inflammatory cytokines in the corneal and conjunctival tissues. This may reduce inflammation, protect the corneal surface from inflammatory-mediated damage and reduce the symptoms of DED.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0061E597-02DE-1CCA-E063-731AD00AED08","latestVersionIndicator":"Yes","beginDate":"2023-07-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-13","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0061EF9E-1A21-1DE2-E063-731AD00A4785","beginDate":"2023-07-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-13","modifiedBy":"GDEEN","dateModified":"2023-07-13","deletedIndicator":"No"},{"value":"Bebtelovimab","valueDescription":null,"ValueMeaning":{"publicId":"14256422","version":"1","preferredName":"Bebtelovimab","longName":"14256422v1.00","preferredDefinition":"A neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, bebtelovimab specifically targets and binds to the receptor-binding domain (RBD) of SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bebtelovimab","conceptCode":"C182122","definition":"A neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, bebtelovimab specifically targets and binds to the receptor-binding domain (RBD) of SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01F8D7F5-2EF9-29FD-E063-731AD00A3BDB","latestVersionIndicator":"Yes","beginDate":"2023-08-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-02","modifiedBy":"GDEEN","dateModified":"2023-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01F8E114-A35D-2B35-E063-731AD00AA0E0","beginDate":"2023-08-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-02","modifiedBy":"GDEEN","dateModified":"2023-08-02","deletedIndicator":"No"},{"value":"Liraglutide","valueDescription":null,"ValueMeaning":{"publicId":"14554869","version":"1","preferredName":"Liraglutide","longName":"14554869v1.00","preferredDefinition":"A long-acting, fatty acylated glucagon-like peptide-1 (GLP-1) analog administered subcutaneously, with antihyperglycemic activity. Liraglutide's prolonged action and half-life of 11-15 hours are attributed to the attachment of the fatty acid palmitic acid to GLP-1 that reversibly binds to albumin. Albumin binding protects liraglutide from immediate degradation and elimination and causes GLP-1 to be released from abumin in a slow and consistent manner. This agent may cause thyroid C-cell tumors and increases the risk of acute pancreatitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liraglutide","conceptCode":"C82239","definition":"A long-acting, fatty acylated glucagon-like peptide-1 (GLP-1) analog administered subcutaneously, with antihyperglycemic activity. Liraglutide's prolonged action and half-life of 11-15 hours are attributed to the attachment of the fatty acid palmitic acid to GLP-1 that reversibly binds to albumin. Albumin binding protects liraglutide from immediate degradation and elimination and causes GLP-1 to be released from abumin in a slow and consistent manner. This agent may cause thyroid C-cell tumors and increases the risk of acute pancreatitis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0830CB5A-345B-0BE7-E063-731AD00A437E","latestVersionIndicator":"Yes","beginDate":"2023-10-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-20","modifiedBy":"GDEEN","dateModified":"2023-10-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0830D12D-37DB-0CCE-E063-731AD00ABE98","beginDate":"2023-10-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-20","modifiedBy":"GDEEN","dateModified":"2023-10-20","deletedIndicator":"No"},{"value":"Anti-spike Protein SARS-CoV-2 Monoclonal Antibody","valueDescription":null,"ValueMeaning":{"publicId":"14554870","version":"1","preferredName":"Anti-spike Protein SARS-CoV-2 Monoclonal Antibody","longName":"14554870v1.00","preferredDefinition":"Any monoclonal antibody that is directed against the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-spike Protein SARS-CoV-2 Monoclonal Antibody","conceptCode":"C173741","definition":"Any monoclonal antibody that is directed against the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0830CB5A-345C-0BE7-E063-731AD00A437E","latestVersionIndicator":"Yes","beginDate":"2023-10-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-20","modifiedBy":"GDEEN","dateModified":"2023-10-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0830D12D-37DC-0CCE-E063-731AD00ABE98","beginDate":"2023-10-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-20","modifiedBy":"GDEEN","dateModified":"2023-10-20","deletedIndicator":"No"},{"value":"Venetoclax","valueDescription":null,"ValueMeaning":{"publicId":"5944045","version":"1","preferredName":"Venetoclax","longName":"5944045","preferredDefinition":"An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Venetoclax","conceptCode":"C103147","definition":"An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E65346-8D8B-6C22-E053-F662850A5722","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"08B6FA59-3BAF-784B-E063-731AD00ABE11","beginDate":"2023-10-27","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-27","modifiedBy":"GDEEN","dateModified":"2023-10-27","deletedIndicator":"No"},{"value":"Alpha-1-Proteinase Inhibitor Human","valueDescription":null,"ValueMeaning":{"publicId":"7631837","version":"1","preferredName":"Alpha-1-Proteinase Inhibitor Human","longName":"7631837","preferredDefinition":"Human serum-derived alpha-1 proteinase inhibitor (alpha-1-antitrypsin or AAT) with immunomodulating and anti-inflammatory activity. Upon administration, AAT reduces the production of proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-32, IL-6, and proteinase 3, and induces the production of anti-inflammatory cytokines, such as IL-10 and the IL-1 receptor antagonist IL-1RN. This agent also downregulates heparan sulfate and reduces the expansion of cytotoxic effector T cells, interferes with the maturation of dendritic cells and increases T regulatory cells. Altogether, AAT may attenuate acute graft-versus-host disease (GvHD) and may facilitate graft acceptance and survival. In addition, AAT enhances levels of cAMP and activation of cAMP-dependent protein kinase A. AAT, a 52kD protein and serine protease inhibitor, belongs to the serpin superfamily.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alpha-1-Proteinase Inhibitor Human","conceptCode":"C82258","definition":"Human serum-derived alpha-1 proteinase inhibitor (alpha-1-antitrypsin or AAT) with immunomodulating and anti-inflammatory activity. Upon administration, AAT reduces the production of proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-32, IL-6, and proteinase 3, and induces the production of anti-inflammatory cytokines, such as IL-10 and the IL-1 receptor antagonist IL-1RN. This agent also downregulates heparan sulfate and reduces the expansion of cytotoxic effector T cells, interferes with the maturation of dendritic cells and increases T regulatory cells. Altogether, AAT may attenuate acute graft-versus-host disease (GvHD) and may facilitate graft acceptance and survival. In addition, AAT enhances levels of cAMP and activation of cAMP-dependent protein kinase A. AAT, a 52kD protein and serine protease inhibitor, belongs to the serpin superfamily.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BFC87F2A-1385-74AF-E053-4EBD850AEF21","latestVersionIndicator":"Yes","beginDate":"2021-04-12","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-04-12","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D999FF0-38B7-0D06-E063-731AD00AFA66","beginDate":"2023-12-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-28","modifiedBy":"GDEEN","dateModified":"2023-12-28","deletedIndicator":"No"},{"value":"Filgrastim","valueDescription":null,"ValueMeaning":{"publicId":"3379062","version":"1","preferredName":"Filgrastim","longName":"3379062","preferredDefinition":"A colony-stimulating factor that stimulates the production of neutrophils (a type of white blood cell). It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called granulocyte colony-stimulating factor (G-CSF).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filgrastim","conceptCode":"C1474","definition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-AD83-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0DFB2778-CF24-7BC0-E063-731AD00AA190","beginDate":"2024-01-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-02","modifiedBy":"GDEEN","dateModified":"2024-01-02","deletedIndicator":"No"},{"value":"Vibegron","valueDescription":null,"ValueMeaning":{"publicId":"14672740","version":"1","preferredName":"Vibegron (Gemtesa)","longName":"14672740v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vibegron","conceptCode":"C152872","definition":"An orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing activity. Upon oral administration, vibegron targets, binds to and activates ADRB3, which leads to relaxation of the detrusor smooth muscle during bladder filling. This increases bladder capacity and provides symptomatic relief, including urge urinary incontinence, urgency, and urinary frequency, for overactive bladder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E216A81-6533-0B42-E063-731AD00A51FA","latestVersionIndicator":"Yes","beginDate":"2024-01-04","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-04","modifiedBy":"GDEEN","dateModified":"2024-01-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E21771D-4570-0DC5-E063-731AD00A52EF","beginDate":"2024-01-04","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-04","modifiedBy":"GDEEN","dateModified":"2024-01-04","deletedIndicator":"No"},{"value":"Prebiotic supplements","valueDescription":null,"ValueMeaning":{"publicId":"14688620","version":"1","preferredName":"Synbiotic Supplement","longName":"14688620v1.00","preferredDefinition":"A nutritional supplement comprised of prebiotic and probiotic ingredients, with potential immunomodulating and gastrointestinal (GI) flora restoring activity. Upon ingestion of the synbiotic supplement, the prebiotics and probiotics work synergistically in the GI tract, thereby modulating the GI flora ecosystem and may improve the functions of the intestinal barrier. In addition, synbiotics may have a beneficial effect on the immune system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Synbiotic Supplement","conceptCode":"C99230","definition":"A nutritional supplement comprised of prebiotic and probiotic ingredients, with potential immunomodulating and gastrointestinal (GI) flora restoring activity. Upon ingestion of the synbiotic supplement, the prebiotics and probiotics work synergistically in the GI tract, thereby modulating the GI flora ecosystem and may improve the functions of the intestinal barrier. In addition, synbiotics may have a beneficial effect on the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F3B2DD9-E62A-795A-E063-731AD00A62FC","latestVersionIndicator":"Yes","beginDate":"2024-01-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-18","modifiedBy":"GDEEN","dateModified":"2024-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F3B2DD9-E633-795A-E063-731AD00A62FC","beginDate":"2024-01-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-18","modifiedBy":"GDEEN","dateModified":"2024-01-18","deletedIndicator":"No"},{"value":"Alrizomadlin","valueDescription":null,"ValueMeaning":{"publicId":"13961798","version":"1","preferredName":"Alrizomadlin","longName":"13961798v1.00","preferredDefinition":"An orally available inhibitor of human homolog of double minute 2 (HDM2; mouse double minute 2 homolog; MDM2), with potential antineoplastic activity. Upon oral administration,alrizomadlin binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alrizomadlin","conceptCode":"C132991","definition":"An orally available inhibitor of human homolog of double minute 2 (HDM2; mouse double minute 2 homolog; MDM2), with potential antineoplastic activity. Upon oral administration,alrizomadlin binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE470C61-592F-4CA4-E053-731AD00ADDA6","latestVersionIndicator":"Yes","beginDate":"2023-06-16","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-06-16","modifiedBy":"GDEEN","dateModified":"2024-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F3B2DD9-E634-795A-E063-731AD00A62FC","beginDate":"2024-01-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-18","modifiedBy":"GDEEN","dateModified":"2024-01-18","deletedIndicator":"No"},{"value":"Alogliptin","valueDescription":null,"ValueMeaning":{"publicId":"2945212","version":"1","preferredName":"Lactation Disorder","longName":"2945212","preferredDefinition":"A disorder not necessarily related to pregnancy that is observed in females and males. It is characterized by disturbances of milk secretion. Causes include damage to the breast parenchyma due to inflammation, medications, pituitary tumors, and hypothyroidism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lactation Disorder","conceptCode":"C79606","definition":"A disorder not necessarily related to pregnancy that is observed in females and males. It is characterized by disturbances of milk secretion. Causes include damage to the breast parenchyma due to inflammation, medications, pituitary tumors, and hypothyroidism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"745580E8-43D5-8FA9-E040-BB89AD433702","latestVersionIndicator":"Yes","beginDate":"2009-09-24","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-24","modifiedBy":"GDEEN","dateModified":"2024-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F3B2DD9-E635-795A-E063-731AD00A62FC","beginDate":"2024-01-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-18","modifiedBy":"GDEEN","dateModified":"2024-01-18","deletedIndicator":"No"},{"value":"Nicotine Gum","valueDescription":null,"ValueMeaning":{"publicId":"3276683","version":"1","preferredName":"Nicotine Gum","longName":"3276683","preferredDefinition":"A chewing gum containing nicotine used as a substitute for the active ingredient in tobacco. Nicotine chewing gum reduces the withdrawal symptoms associated with smoking cessation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nicotine Gum","conceptCode":"C15663","definition":"A chewing gum containing nicotine used as a substitute for the active ingredient in tobacco. Nicotine chewing gum reduces the withdrawal symptoms associated with smoking cessation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACFBB39A-964C-633A-E040-BB89AD436C25","latestVersionIndicator":"Yes","beginDate":"2011-09-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFD90-3E2E-04E2-E063-731AD00A317C","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Zotiraciclib Citrate","valueDescription":null,"ValueMeaning":{"publicId":"13746575","version":"1","preferredName":"Zotiraciclib Citrate","longName":"13746575v1.00","preferredDefinition":"An orally bioavailable citrate salt form of zotiraciclib a multi-kinase inhibitor for cyclin dependent kinase (CDK) subtypes 1, 2, 7 and 9, Janus-associated kinase 2 (JAK2), FMS-related tyrosine kinase 3 (FLT3, FLK2, STK1), with potential antineoplastic activity. Upon oral administration, CDK/JAK2/FLT3 Inhibitor TG02 binds to and inhibits the CDK subtypes, JAK2, and FLT3. TG02 also inhibits, to a lesser extent, TYK2, TYRO3, STAT5 and P38delta. This may result in both an induction of apoptosis and an inhibition of tumor cell proliferation in cancer cells that overexpress these kinases. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival. CDKs are serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zotiraciclib Citrate","conceptCode":"C105851","definition":"An orally bioavailable citrate salt form of zotiraciclib a multi-kinase inhibitor for cyclin dependent kinase (CDK) subtypes 1, 2, 7 and 9, Janus-associated kinase 2 (JAK2), FMS-related tyrosine kinase 3 (FLT3, FLK2, STK1), with potential antineoplastic activity. Upon oral administration, CDK/JAK2/FLT3 Inhibitor TG02 binds to and inhibits the CDK subtypes, JAK2, and FLT3. TG02 also inhibits, to a lesser extent, TYK2, TYRO3, STAT5 and P38delta. This may result in both an induction of apoptosis and an inhibition of tumor cell proliferation in cancer cells that overexpress these kinases. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival. CDKs are serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCA66669-55B6-6FE3-E053-731AD00A12E6","latestVersionIndicator":"Yes","beginDate":"2023-05-27","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-27","modifiedBy":"GDEEN","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFD90-3E2F-04E2-E063-731AD00A317C","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"NovoTTF-100A Device","valueDescription":null,"ValueMeaning":{"publicId":"7717906","version":"1","preferredName":"NovoTTF-100A Device","longName":"7717906","preferredDefinition":"A portable, battery-operated device that is used to apply low intensity, alternating electric fields, also called tumor treatment fields (TTFs; TTFields), that can potentially be used to kill cancer cells. Upon placement of the insulated electrodes of the NovoTTF-100A device on the skin's surface encircling the tumor area, electrical charges are delivered, and the resulting electrical fields interfere with cell division. This induces cell death in and inhibits proliferation of tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NovoTTF-100A Device","conceptCode":"C125103","definition":"A portable, battery-operated device that is used to apply low intensity, alternating electric fields, also called tumor treatment fields (TTFs; TTFields), that can potentially be used to kill cancer cells. Upon placement of the insulated electrodes of the NovoTTF-100A device on the skin's surface encircling the tumor area, electrical charges are delivered, and the resulting electrical fields interfere with cell division. This induces cell death in and inhibits proliferation of tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C68E0707-A38D-1753-E053-4EBD850AA75A","latestVersionIndicator":"Yes","beginDate":"2021-07-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-07-07","modifiedBy":"GDEEN","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFD90-3E30-04E2-E063-731AD00A317C","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Valproic Acid","valueDescription":null,"ValueMeaning":{"publicId":"7460887","version":"1","preferredName":"Valproic Acid","longName":"7460887","preferredDefinition":"A synthetic derivative of propylpentanoic acid with antiepileptic properties and potential antineoplastic and antiangiogenesis activities.  In epilepsy, valproic acid appears to act by increasing the concentration of gamma-aminobutyric acid (GABA) in the brain. This agent's antitumor and antiangiogenesis activities may be related to the inhibition of histone deacetylases and nitric oxide synthase, which results in the inhibition of nitric oxide synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Valproic Acid","conceptCode":"C29536","definition":"A synthetic derivative of propylpentanoic acid with antiepileptic properties and potential antineoplastic and antiangiogenesis activities.  In epilepsy, valproic acid appears to act by increasing the concentration of gamma-aminobutyric acid (GABA) in the brain. This agent's antitumor and antiangiogenesis activities may be related to the inhibition of histone deacetylases and nitric oxide synthase, which results in the inhibition of nitric oxide synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D54F-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFD90-3E31-04E2-E063-731AD00A317C","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Topical Leptospermum Honey","valueDescription":null,"ValueMeaning":{"publicId":"14737557","version":"1","preferredName":"Topical Leptospermum Honey","longName":"14737557v1.00","preferredDefinition":"A topical formulation composed of active Leptospermum honey (ALH), a monofloral honey produced by bees fed on the flowers of the New Zealand Manuka bush (Leptospermum scoparium), with potential wound repair, antibacterial, anti-inflammatory, and protective activities. Upon administration of topical Leptospermum honey, the active ingredients in this honey may promote healing, and prevent inflammation and infection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topical Leptospermum Honey","conceptCode":"C203678","definition":"A topical formulation composed of active Leptospermum honey (ALH), a monofloral honey produced by bees fed on the flowers of the New Zealand Manuka bush (Leptospermum scoparium), with potential wound repair, antibacterial, anti-inflammatory, and protective activities. Upon administration of topical Leptospermum honey, the active ingredients in this honey may promote healing, and prevent inflammation and infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"102FFBCF-5CF7-046F-E063-731AD00AD14D","latestVersionIndicator":"Yes","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFD90-3E32-04E2-E063-731AD00A317C","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"DRD2 Antagonist/ClpP Agonist ONC206","valueDescription":null,"ValueMeaning":{"publicId":"14483679","version":"1","preferredName":"DRD2 Antagonist/ClpP Agonist ONC206","longName":"14483679v1.00","preferredDefinition":"An orally bioavailable, selective bitopic dopamine receptor D2 (DRD2) antagonist and mitochondrial caseinolytic protease P (ClpP) agonist, with potential antineoplastic activity. Upon administration, DRD2 antagonist/ClpP agonist ONC206 targets, binds to and inhibits the activity of DRD2. This may inactivate Akt (protein kinase B) and extracellular signal-regulated kinase (ERK), which may result in inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway as well as the mitogen-activated protein kinase (MAPK)/ERK-mediated pathway. This may lead to the induction of tumor cell apoptosis mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/death receptor type 5 (DR5; TRAIL receptor 2) signaling in tumor cells. In addition, ONC206 targets and binds to ClpP and induces proteolysis. This may disrupt mitochondrial structure and function in tumor cells and lead to tumor cell death. DRD2, a G protein-coupled receptor (GPCR), is overexpressed in various malignancies. It is activated by dopamine produced by the tumor cells or present in the tumor microenvironment (TME) and plays an important role in the pro-survival and stress signaling pathways. ONC206 is able to cross the blood-brain barrier (BBB).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DRD2 Antagonist/ClpP Agonist ONC206","conceptCode":"C176975","definition":"An orally bioavailable, selective bitopic dopamine receptor D2 (DRD2) antagonist and mitochondrial caseinolytic protease P (ClpP) agonist, with potential antineoplastic activity. Upon administration, DRD2 antagonist/ClpP agonist ONC206 targets, binds to and inhibits the activity of DRD2. This may inactivate Akt (protein kinase B) and extracellular signal-regulated kinase (ERK), which may result in inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway as well as the mitogen-activated protein kinase (MAPK)/ERK-mediated pathway. This may lead to the induction of tumor cell apoptosis mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/death receptor type 5 (DR5; TRAIL receptor 2) signaling in tumor cells. In addition, ONC206 targets and binds to ClpP and induces proteolysis. This may disrupt mitochondrial structure and function in tumor cells and lead to tumor cell death. DRD2, a G protein-coupled receptor (GPCR), is overexpressed in various malignancies. It is activated by dopamine produced by the tumor cells or present in the tumor microenvironment (TME) and plays an important role in the pro-survival and stress signaling pathways. ONC206 is able to cross the blood-brain barrier (BBB).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05BC7C2E-28A5-5471-E063-731AD00AEA2B","latestVersionIndicator":"Yes","beginDate":"2023-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-19","modifiedBy":"GDEEN","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFD90-3E33-04E2-E063-731AD00A317C","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Protein Phosphatase 2A Inhibitor LB-100","valueDescription":null,"ValueMeaning":{"publicId":"13724985","version":"1","preferredName":"Protein Phosphatase 2A Inhibitor LB-100","longName":"13724985v1.00","preferredDefinition":"A water soluble inhibitor of the protein phosphatase 2A (PP2A), with potential chemo- and radiotherapy enhancing activity. Upon injection, PP2A inhibitor LB-100 inhibits the removal of phosphate groups from proteins essential for cell cycle progression. When used with radio- or chemotherapy treatment, this agent prevents the activation of PP2A-mediated repair mechanisms and allows for malignant cells to progress through the cell cycle without having their damaged DNA repaired. This enhances the cytotoxic effect of the chemotherapeutic or radiotherapeutic agent and results in tumor cell apoptosis. PP2A, a serine/threonine phosphatase that plays a key role in the control of cell growth and DNA damage repair.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protein Phosphatase 2A Inhibitor LB-100","conceptCode":"C106430","definition":"A water soluble inhibitor of the protein phosphatase 2A (PP2A), with potential chemo- and radiotherapy enhancing activity. Upon injection, PP2A inhibitor LB-100 inhibits the removal of phosphate groups from proteins essential for cell cycle progression. When used with radio- or chemotherapy treatment, this agent prevents the activation of PP2A-mediated repair mechanisms and allows for malignant cells to progress through the cell cycle without having their damaged DNA repaired. This enhances the cytotoxic effect of the chemotherapeutic or radiotherapeutic agent and results in tumor cell apoptosis. PP2A, a serine/threonine phosphatase that plays a key role in the control of cell growth and DNA damage repair.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC9F3F8C-ECF4-2D42-E053-731AD00AFB41","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-26","modifiedBy":"DWARZEL","dateModified":"2023-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFD90-3E34-04E2-E063-731AD00A317C","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Galcanezumab-gnlm","valueDescription":null,"ValueMeaning":{"publicId":"14741291","version":"1","preferredName":"Galcanezumab","longName":"14741291v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Galcanezumab","conceptCode":"C166816","definition":"A humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting calcitonin-gene related peptide (CGRP) ligand, that can be used in the preventive treatment of migraine. Upon subcutaneous administration, galcanezumab specifically targets and binds to CGRP ligand, and blocks the binding of the CGRP ligand to its receptor. This blocks the CGRP pathway and prevents migraine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"105629E4-1268-7709-E063-731AD00A5990","latestVersionIndicator":"Yes","beginDate":"2024-02-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-01","modifiedBy":"GDEEN","dateModified":"2024-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10563156-5BDF-784D-E063-731AD00A44FD","beginDate":"2024-02-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-01","modifiedBy":"GDEEN","dateModified":"2024-02-01","deletedIndicator":"No"},{"value":"Pamiparib","valueDescription":null,"ValueMeaning":{"publicId":"13715000","version":"1","preferredName":"Pamiparib","longName":"13715000v1.00","preferredDefinition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), with potential antineoplastic activity. Upon administration, pamiparib selectively binds to PARP and prevents PARP-mediated repair of single-strand DNA breaks via the base-excision repair (BER) pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability, and eventually leads to apoptosis. PARP is activated by single-strand DNA breaks and, subsequently, catalyzes post-translational ADP-ribosylation of nuclear proteins which then transduce signals to recruit other proteins to repair damaged DNA. Pamiparib may both potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell chemo- and radioresistance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pamiparib","conceptCode":"C120553","definition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), with potential antineoplastic activity. Upon administration, pamiparib selectively binds to PARP and prevents PARP-mediated repair of single-strand DNA breaks via the base-excision repair (BER) pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability, and eventually leads to apoptosis. PARP is activated by single-strand DNA breaks and, subsequently, catalyzes post-translational ADP-ribosylation of nuclear proteins which then transduce signals to recruit other proteins to repair damaged DNA. Pamiparib may both potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell chemo- and radioresistance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC9CCF12-BD7C-3766-E053-731AD00A3FED","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-26","modifiedBy":"GDEEN","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A64490-A71F-22DA-E063-731AD00A4DAA","beginDate":"2024-02-05","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-05","modifiedBy":"GDEEN","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"Cabergoline","valueDescription":null,"ValueMeaning":{"publicId":"3378839","version":"1","preferredName":"Cabergoline","longName":"3378839","preferredDefinition":"A synthetic ergoline derivative and a long-acting dopamine receptor agonist with high affinity for the dopamine D2 receptor. Cabergoline exerts an inhibitory effect on prolactin secretion by acting on dopamine receptors present in pituitary lactotrophs. This drug also binds to dopamine D2 receptors in the corpus striatum, thereby mimicking the actions of dopamine on motor control. Cabergoline also possesses antioxidant and neuroprotective properties due to its free radical scavenging activity. Cabergoline is used in the treatment of Parkinson's disease and in the treatment of hyperprolactinemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cabergoline","conceptCode":"C47428","definition":"A synthetic ergoline derivative and a long-acting dopamine receptor agonist with high affinity for the dopamine D2 receptor. Cabergoline exerts an inhibitory effect on prolactin secretion by acting on dopamine receptors present in pituitary lactotrophs. This drug also binds to dopamine D2 receptors in the corpus striatum, thereby mimicking the actions of dopamine on motor control. Cabergoline also possesses antioxidant and neuroprotective properties due to its free radical scavenging activity. Cabergoline is used in the treatment of Parkinson's disease and in the treatment of hyperprolactinemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-176C-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"11469271-0466-12E1-E063-731AD00AC94F","beginDate":"2024-02-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-13","modifiedBy":"GDEEN","dateModified":"2024-02-13","deletedIndicator":"No"},{"value":"Brinzolamide","valueDescription":null,"ValueMeaning":{"publicId":"14770128","version":"1","preferredName":"Brinzolamide (Azopt)","longName":"14770128v1.00","preferredDefinition":"A sulfonamide and carbonic anhydrase inhibitor with specific affinity for carbonic anhydrase II. Following topical ocular administration, brinzolamide inhibits carbonic anhydrase II, an enzyme that is responsible for the movement of sodium and fluid transport in the eye. This inhibition leads to a decrease in aqueous humor secretion, probably by slowing the formation of bicarbonate ions, and results in a reduction in intraocular pressure. Brinzolamide is used to treat increased pressure in the eye caused by open-angle glaucoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brinzolamide","conceptCode":"C47420","definition":"A sulfonamide and carbonic anhydrase inhibitor with specific affinity for carbonic anhydrase II. Following topical ocular administration, brinzolamide inhibits carbonic anhydrase II, an enzyme that is responsible for the movement of sodium and fluid transport in the eye. This inhibition leads to a decrease in aqueous humor secretion, probably by slowing the formation of bicarbonate ions, and results in a reduction in intraocular pressure. Brinzolamide is used to treat increased pressure in the eye caused by open-angle glaucoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11EB7D48-1049-3ACB-E063-731AD00AF3DC","latestVersionIndicator":"Yes","beginDate":"2024-02-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-21","modifiedBy":"GDEEN","dateModified":"2024-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"11EB81D2-02B0-3BCB-E063-731AD00A27A4","beginDate":"2024-02-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-21","modifiedBy":"GDEEN","dateModified":"2024-02-21","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3126074","version":"1","preferredName":"Post-Therapy Agent Name","preferredDefinition":"No Value Exists:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI):The words or language units by which a thing is known.","longName":"C54735:C1708:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post-Therapy","conceptCode":"C54735","definition":"Occurring after a therapeutic procedure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8CEC9CF9-F389-77C5-E040-BB89AD437145","latestVersionIndicator":"Yes","beginDate":"2010-08-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"ONEDATA","dateModified":"2010-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8CEC9CF9-F39A-77C5-E040-BB89AD437145","latestVersionIndicator":"Yes","beginDate":"2010-08-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"GDEEN","dateModified":"2024-02-21","changeDescription":null,"administrativeNotes":"2023.9.22 Updated PV def for 'No value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Post-Therapy Followup Agent","type":"Preferred Question Text","description":"Post-Therapy Followup Agent","url":null,"context":"CCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8CEC9CF9-F4CF-77C5-E040-BB89AD437145","latestVersionIndicator":"Yes","beginDate":"2010-08-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-03","modifiedBy":"REEVESD","dateModified":"2011-07-28","changeDescription":"Curated for CCR studies","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}